ENMD2076 is primarily investigated for its potential in cancer therapy, particularly in targeting specific signaling pathways involved in tumor growth and angiogenesis. It has shown promise in preclinical studies for treating various cancers, including breast cancer, ovarian cancer, and leukemia, by inhibiting kinases that play a role in cancer progression. Additionally, ENMD2076 is being explored for its efficacy in combating drug-resistant cancers, offering a potential therapeutic option where traditional treatments have failed. Its ability to selectively target cancer cells while minimizing damage to healthy tissues makes it a candidate for further clinical development.